Pharmacokinetic interactions: The drug interaction potential resulting in changes of piracetam (Nootropil) pharmacokinetics is expected to be low because approximately 90% of the dose of piracetam (Nootropil) is excreted in the urine as unchanged drug.
In vitro, piracetam (Nootropil) does not inhibit the human liver cytochrome P450 isoforms CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 4A9/11 at concentrations of 142, 426 and 1422 μg/mL.
At 1422 μg/mL, minor inhibitory effects on CYP 2A6 (21%) and 3A4/5 (11%) were observed. However, the Ki values for inhibition of these two CYP isoforms are likely to be well in excess of 1422 μg/mL. Therefore, metabolic interaction of piracetam (Nootropil) with other drugs is unlikely.
Thyroid hormones: Confusion, irritability and sleep disorder have been reported during concomitant treatment with thyroid extract (T3 + T4).
Acenocoumarol: In a published single-blind study on patients with severe recurrent venous thrombosis, piracetam (Nootropil) 9.6 g/d did not modify the doses of acenocoumarol necessary to reach INR 2.5 to 3.5, but compared with the effects of acenocoumarol alone, the addition of piracetam (Nootropil) 9.6 g/d significantly decreased platelet aggregation, β-thromboglobulin release, levels of fibrinogen and von Willebrand’s factors (VIII: C; VIII: vW: Ag; VIII: vW : RCo) and whole blood and plasma viscosity.
Antiepileptic drugs: A 20 g daily dose of piracetam (Nootropil) over 4 weeks did not modify the peak and trough serum levels of antiepileptic drugs (carbamazepine, phenytoin, phenobarbitone, valproate) in epileptic patients who were receiving stable doses.
Alcohol: Concomitant administration of alcohol had no effect on piracetam (Nootropil) serum levels and alcohol levels were not modified by a 1.6 g oral dose of piracetam (Nootropil).